Clinical Trials Logo

CCR5 clinical trials

View clinical trials related to CCR5.

Filter by:
  • None
  • Page 1

NCT ID: NCT05730673 Withdrawn - Colorectal Cancer Clinical Trials

Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Start date: September 20, 2022
Phase: Phase 2
Study type: Interventional

This is aPhase II Study of Leronlimab (PRO 140) in combination with Regorafenib in Patients with CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

NCT ID: NCT02990312 Withdrawn - Hiv Clinical Trials

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

Start date: May 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this proof of concept, pilot study is to determine whether the unique combination of the human immunodeficiency virus (HIV) co-receptor antagonist, Maraviroc, and the mammalian target of rapamycin (mTOR) inhibitor, Sirolimus, in HIV-infected kidney transplant recipients has an impact on chemokine receptor 5 (CCR5) density, the HIV-reservoir, or rejection of the transplanted kidney. 15 HIV-infected kidney transplant recipients will be recruited and their immunosuppressant regimen will be changed to include an mTOR inhibitor (such as Sirolimus) unless they are already on one. In addition, Maraviroc will be added to their HIV regimen, unless they are already on Maraviroc. Blood will be taken to measure markers of the HIV reservoir, their CCR5 density and expression, and immune activation.